Psoriasis and Psoriatic Arthritis
FDA Approved Therapies
Description
Cimzia® decreases inflammation in the body by binding to and blocking a protein called tumor necrosis factor alpha. It is FDA approved for the treatment of active psoriatic arthritis.
Dosing and Administration
Cimzia® can be self-administered subcutaneously. The recommended dose for Cimzia® is 400 mg initially, and at weeks 2 and 4, and then 200 mg every 2 weeks (400 mg every 4 weeks can also be considered for maintenance dosing).
Common Side Effects
The most common side effects of tumor necrosis factor inhibitors include infusion or injection site reactions, upper respiratory infections, and allergic reactions. There is also a slight risk of more serious side effects including lymphoma and serious infections.
Description
Cosentyx® decreases inflammation in the body by binding to and blocking a protein called IL-17. It is FDA approved for the treatment of adults with moderate to severe plaque psoriasis and in patients with psoriatic arthritis.
Dosing and Administration
Cosentyx ® can be self-administered subcutaneously. The recommended dose for plaque psoriasis is 300 mg weekly for five doses, and then 300 mg every 4 weeks (For some patients, a dosage of 150 mg may be acceptable). For patients with psoriatic arthritis (without coexistent moderate to severe plaque psoriasis), the dose should be 150 mg weekly for five doses, and then 150 mg every 4 weeks.
Common Side Effects
The most common side effects of IL-17 inhibitors include increased risk of infection or upper respiratory infections, and allergic reactions.
Description
Enbrel® decreases inflammation in the body by binding to and blocking a protein called tumor necrosis factor alpha. It is FDA approved for the treatment of adults with moderate to severe plaque psoriasis and in patients with psoriatic arthritis.
Dosing and Administration
Enbrel® can be self-administered subcutaneously. The recommended starting dose for plaque psoriasis is 50 mg twice weekly for three months followed by 50 mg once weekly. The recommended dose for psoriatic arthritis is 50 mg once weekly.
Common Side Effects
The most common side effects of tumor necrosis factor inhibitors include infusion or injection site reactions, upper respiratory infections, and allergic reactions. There is also a slight risk of more serious side effects including lymphoma and serious infections.
Description
Humira® decreases inflammation in the body by binding to and blocking a protein called tumor necrosis factor alpha. It is FDA approved for the treatment of adults with moderate to severe plaque psoriasis and in patients with psoriatic arthritis.
Dosing and Administration
Humira® can be self-administered subcutaneously. The recommended starting dose for plaque psoriasis is 80 mg followed by 40 mg every other week starting one week after the initial dose. The recommended dose for psoriatic arthritis is 40 mg every other week.
Common Side Effects
The most common side effects of tumor necrosis factor inhibitors include infusion or injection site reactions, upper respiratory infections, and allergic reactions. There is also a slight risk of more serious side effects including lymphoma and serious infections.
Description
Otezla® is an oral tablet that decreases inflammation in the body. It is FDA approved for the treatment of psoriasis and active psoriatic arthritis.
Dosing and Administration
The recommended maintenance dose for Otezla® is 30 mg twice daily. Patients should follow a prescribed 5-day dose titration protocol before reaching the maximum dose. Dosage should be reduced to 30 mg once daily in patients with severe renal impairment.
Common Side Effects
The most common side effects include diarrhea, nausea, upper respiratory tract infection, and headache. Emergence or worsening of depression, suicidal thoughts, or other mood changes may also occur.
Description
Remicade® decreases inflammation in the body by binding to and blocking a protein called tumor necrosis factor alha. It is FDA approved for the treatment of adults with chronic severe plaque psoriasis and in patients with psoriatic arthritis.
Dosing and Administration
Remicade® is an infused medication and should be administered by health care professionals only. The recommended dose for Remicade® in adult patients with plaque psoriasis or psoriatic arthritis is 5 mg/kg initially, at weeks 2 and 6, and then every 8 weeks.
Common Side Effects
The most common side effects of tumor necrosis factor inhibitors include infusion or injection site reactions, upper respiratory infections, and allergic reactions. There is also a slight risk of more serious side effects including lymphoma and serious infections.
Description
Simponi® decreases inflammation in the body by binding to and blocking a protein called tumor necrosis factor alpha. It is FDA approved for the treatment of active psoriatic arthritis.
Dosing and Administration
Simponi® can be self-administered subcutaneously. The recommended dose for Simponi® in adult patients 50 mg once a month.
Common Side Effects
The most common side effects of tumor necrosis factor inhibitors include infusion or injection site reactions, upper respiratory infections, and allergic reactions. There is also a slight risk of more serious side effects including lymphoma and serious infections.
Description
Stelara® decreases inflammation in the body by binding to and blocking proteins called IL-12 and IL-23. It is FDA approved for the treatment of adults with moderate to severe plaque psoriasis and in patients with psoriatic arthritis.
Dosing and Administration
Stelara® can be self-administered subcutaneously. The recommended dose for Stelara® in adult patients with psoriasis or psoriatic arthritis is 45 mg initially followed by 45 mg every 12 weeks. For patients that weight more than 100 mg, this dose should be increased to 90 mg.
Common Side Effects
The most common side effects of Stelara® include naropharyngitis, upper respiratory infections, headache, tiredness, and fatigue. There is also a slight risk of more serious side effects including risk of serious infections and reactivation of latent infections.
Description
Taltz® decreases inflammation in the body by binding to and blocking a protein called IL-17. It is FDA approved for the treatment of adults with moderate to severe plaque psoriasis.
Dosing and Administration
Taltz® can be self-administered subcutaneously. The recommended dose for plaque psoriasis is 160 mg (two 80 mg injections) every other week for seven doses, and then 80 mg every 4 weeks.
Common Side Effects
The most common side effects of IL-17 inhibitors include increased risk of infection or upper respiratory infections, and allergic reactions.